The rates after conventional EGFR-TKI treatment were 4% in the AURA3 study and 7.3% in the Japanese subset of patients, which suggests that Japanese patients may have a higher rate of pneumonitis [13,34]. The gene discussed is EGFR; the disease is pneumonitis.